Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(23 sites) United States
Banner MD Anderson Cancer Center, Gilbert, Arizona City of Hope, Duarte, California H. Lee Moffitt Cancer Center, Tampa, Florida Winship Cancer Institute Emory University, Atlanta, Georgia Northside Hospital Cancer Institute, Atlanta, Georgia University of Maryland, Baltimore, Maryland Tufts Medical Center, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit, Michigan University of Minnesota, Minneapolis, Minnesota Weill Cornell Medical College - NY Presbyterian Hospital, New York, New York Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York Duke University, Durham, North Carolina Ohio State University, Columbus, Ohio Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island Baylor University Medical Center, Dallas, Texas MD Anderson, Houston, Texas Medical College of Wisconsin, Milwaukee, Wisconsin Australia
Royal Prince Alfred Hospital, Camperdown, New South Wales Liverpool Hospital, Liverpool, New South Wales Royal Adelaide Hospital, Adelaide, South Australia St Vincent's Hospital Melbourne, Fitzroy, Victoria Barwon Health - Andrew Love Cancer Centre, Geelong, Victoria